bluebird bio
BLUE
BLUE was delisted on the 30th of May, 2025.
175 hedge funds and large institutions have $309M invested in bluebird bio in 2023 Q2 according to their latest regulatory filings, with 27 funds opening new positions, 67 increasing their positions, 41 reducing their positions, and 29 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
63% more repeat investments, than reductions
Existing positions increased: 67 | Existing positions reduced: 41
0.17% less ownership
Funds ownership: 4.58% → 4.41% (-0.17%)
0% less capital invested
Capital invested by funds: $310M → $309M (-$950K)
7% less first-time investments, than exits
New positions opened: 27 | Existing positions closed: 29
1% less funds holding
Funds holding: 177 → 175 (-2)
32% less call options, than puts
Call options by funds: $3.89M | Put options by funds: $5.74M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
+$12.5M |
| 2 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$9.87M |
| 3 |
PAMS
Pictet Asset Management (Switzerland)
Geneva 73,
Switzerland
|
+$5.71M |
| 4 |
Walleye Capital
New York
|
+$3.06M |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$2.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
-$9.14M |
| 2 |
DM
Deerfield Management
New York
|
-$6.92M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$6.37M |
| 4 |
Millennium Management
New York
|
-$5.15M |
| 5 |
State Street
Boston,
Massachusetts
|
-$5.15M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
201
Baillie Gifford & Co
Edinburgh,
United Kingdom
| – | -$2.73K | -43 | Closed |
|
|
AAS
202
Ameritas Advisory Services
Lincoln,
Nebraska
| – | -$2.41K | -35 | Closed |
|
|
EI
203
Ellevest Inc
New York
| – | -$1.53K | -24 | Closed |
|
|
AA
204
Ancora Advisors
Cleveland,
Ohio
| – | -$238 | -4 | Closed |
|
BLUE Hedge Fund Activity: Q2 2023 in Review
175 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in bluebird bio (BLUE) for Q2 2023, worth a combined $309M — down 0.31% from $310M a quarter earlier.
Sellers outnumbered buyers: 29 funds closed out of BLUE and 27 opened new positions — a net loss of 2 holders — while 41 trimmed existing stakes and 67 added.
The largest buyer was Granahan Investment Management, adding an estimated $12.5M. The largest seller was Tang Capital Management, cutting an estimated $9.14M.
- 175 institutional investors held bluebird bio (BLUE) as of Q2 2023, down from 177 in Q1 2023.
- Funds reported $309M of bluebird bio stock for Q2 2023, down 0.31% quarter-over-quarter.
- 27 funds opened new bluebird bio positions in Q2 2023 and 29 closed out, a net change of -2 holders.
- The largest bluebird bio buyer in Q2 2023 was Granahan Investment Management, an estimated $12.5M added.
- The largest bluebird bio seller in Q2 2023 was Tang Capital Management, an estimated $9.14M sold.
Based on aggregated 13F filings for Q2 2023.